ID2 and rheumatoid arthritis: To further assess the impact of activation inhibition on Id2 and cytokine secretion in RA patients, we divided 51 patients into the TNFi group (n = 26) and ABA group (n = 25) based on their treatment protocols and monitored them during the 12‐week treatment period.